Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Hossein Borghaei(Fox Chase Cancer Center), Wallace Akerley(University of Utah), Hirva Mamdani(Wayne State University), Andrew Elliott(Caris Life Sciences (United States)), Bhakti Dwivedi(Emory University), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Andrei A. Ivanov, Shiven B. Patel(Huntsman Cancer Institute), Sonam Puri(University of Utah), Gabriel Sica(UPMC Hillman Cancer Center), Gilberto Lopes(University of Miami), Florian Kocher(Innsbruck Medical University), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Balázs Halmos(Montefiore Medical Center), Andreas Seeber(Innsbruck Medical University), Amit Kulkarni(University of Minnesota), Abdul Rafeh Naqash(Oklahoma City University), Kathleen Kerrigan(University of Utah)
Cited by 3
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k